Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Del Giudice, I
Right arrow Articles by Catovsky, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Del Giudice, I
Right arrow Articles by Catovsky, D
Haematologica, Vol 89, Issue 3, 303-308
Copyright © 2004 by Ferrata Storti Foundation

Clinical Trial

The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes

I Del Giudice, E Matutes, R Morilla, A Morilla, K Owusu-Ankomah, F Rafiq, R A'Hern, J Delgado, MB Bazerbashi, and D Catovsky

Academic Department of Hematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London, UK.

BACKGROUND AND OBJECTIVES: CD123 is an antibody that identifies the a chain of the human interleukin-3 receptor and is expressed in a variety of normal hematopoietic cells, acute leukemia and hairy cell leukemia (HCL). The aim of the study was to investigate the diagnostic value of CD123 expression in B-cell disorders with circulating hairy and villous lymphocytes. DESIGN AND METHODS: We investigated the diagnostic value of CD123 expression in neoplastic cells from 59 patients with B-cell disorders with circulating hairy or villous lymphocytes: HCL (n=24), the variant form of HCL (n=11) and splenic lymphoma with villous lymphocytes (SLVL) (n=24). Cells from 12 patients with chronic lymphocytic leukemia were used as controls. Immunophenotypic analysis was performed by flow cytometry on 77 samples from peripheral blood (n=48), bone marrow (n=25) and spleen cell suspensions (n=4). RESULTS: Our findings show that cells from 95% of typical HCL express CD123 with strong to moderate intensity while this molecule is absent in circulating cells from most cases of HCL-variant (91%) and SLVL (97%). INTERPRETATION AND CONCLUSIONS: We conclude that CD123 is a useful new marker for distinguishing B-cell disorders with circulating villous lymphocytes as its expression is characteristic of typical HCL with high sensitivity and specificity. However CD123 does not allow the distinction between HCL-variant and SLVL, as both are CD123 negative.


This article has been cited by other articles:


Home page
 BloodHome page
A. Traverse-Glehen, L. Baseggio, E. C. Bauchu, D. Morel, S. Gazzo, M. Ffrench, A. Verney, D. Rolland, C. Thieblemont, J.-P. Magaud, et al.
Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
Blood, February 15, 2008; 111(4): 2253 - 2260.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.